Uses and Therapeutic Indications

Deltius is a pharmacological preparation of cholecalciferol, commonly known as vitamin D3. It is primarily indicated for the prevention and treatment of vitamin D deficiency in adults, adolescents, and children. Cholecalciferol is a fat-soluble vitamin that the body normally synthesizes through skin exposure to ultraviolet light or obtains through specific dietary sources.

The primary clinical uses of this medication include:

• Treatment of Vitamin D Deficiency: Used to restore healthy levels of vitamin D in individuals who have been diagnosed with a deficiency through clinical assessment or laboratory testing.
• Prevention of Deficiency: Prescribed to individuals at high risk of developing a deficiency, such as those with limited sun exposure, malabsorption syndromes, or specific dietary restrictions.
• Adjunctive Therapy for Osteoporosis: Often used in combination with specific osteoporosis treatments to ensure adequate vitamin D levels, which are necessary for the maintenance of bone density.

Mechanism of Action and Benefits

The active ingredient in Deltius plays a fundamental role in calcium homeostasis and bone mineralization. The benefits of maintaining adequate levels through treatment include:

Calcium and Phosphate Regulation

Vitamin D3 increases the efficiency of the small intestine in absorbing dietary calcium and phosphorus. These minerals are essential for the development and maintenance of a strong skeletal structure. Without sufficient vitamin D, the body cannot absorb enough calcium, which may lead to the weakening of bones.

Bone Health Maintenance

By regulating mineral levels, cholecalciferol supports the continuous process of bone remodeling. In pediatric patients, it is essential for the proper development of the skeleton. In adults and the elderly, it helps maintain bone mass and reduces the risk of bone softening, a condition known as osteomalacia.

Support of Neuromuscular Function

Adequate vitamin D levels contribute to normal muscle function. This is particularly important for physical stability and balance, as vitamin D receptors are present in human skeletal muscle tissue.

Deltius contains cholecalciferol, which is Vitamin D3, and is primarily used to prevent or treat Vitamin D deficiency, as well as associated bone conditions like rickets and osteomalacia. Most adults and children can use this supplement.

However, Deltius may not be suitable for all individuals. Your healthcare provider must be informed if you have or have previously experienced any of the following conditions:

---

Contraindication	Reason for Caution
Hypercalcemia	High levels of calcium in the blood
Hypercalciuria	High levels of calcium in the urine
Hypervitaminosis D	High levels of Vitamin D in the blood
Kidney problems	May include kidney failure or a history of kidney stones
Malabsorption syndrome	Conditions where nutrients are poorly absorbed from food
Sarcoidosis	A rare inflammatory disease
Known allergy	Hypersensitivity to cholecalciferol or any ingredients

---

If you are pregnant or breastfeeding, you should consult a doctor before using Deltius, as dose requirements may change. It is also important to tell your doctor about all other medicines, vitamins, or supplements you are taking to check for potential drug interactions.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Colecalciferol (Deltius) through its effects on mineral balance and its own absorption and metabolism. No medicinal products are explicitly classified as formal contraindicated combinations solely due to interaction risk.

Interaction Type	Interacting Agents (Examples)	Official Regulatory Statement
Pharmacodynamic	Thiazide Diuretics (e.g., Bendroflumethiazide), Calcium-containing products	Increase the documented risk of hypercalcaemia by reducing urinary calcium excretion or additive effects. The effects of Cardiac Glycosides (e.g., Digoxin) may be accentuated due to elevated calcium levels.
Metabolic/PK	Anticonvulsants (e.g., Phenytoin, Carbamazepine), Glucocorticoids	Can decrease the effect of Colecalciferol due to metabolic activation (increased catabolism) or inhibited conversion of Vitamin D [2.4].
Absorption/PK	Bile Acid Sequestrants (e.g., Cholestyramine), Liquid Paraffin, Orlistat	Reduce the gastrointestinal absorption of the fat-soluble Colecalciferol [2.3].

Special Requirements and Constraints:

• Timing Separation: Dose separation is required for absorption-blocking medicines; for example, taking Colecalciferol at least 1 hour before or 4 hours after Bile Acid Sequestrants [4.2].
• Food Interaction: Absorption of Colecalciferol is enhanced when the medicine is taken with a large meal.
• Aluminum: Colecalciferol can increase the body's absorption of aluminum from antacids.
• Population Note: Monitoring of serum calcium is specified as especially important for elderly patients concurrently using cardiac glycosides or thiazide diuretics, and aluminum risk is a specific concern for patients with renal impairment [2.4].

This structure reflects the regulatory focus on managing the potential for mineral imbalance and ensuring effective drug absorption when Deltius is co-administered with other substances.

Deltius is a small molecule that acts as an allosteric modulator of the FPPS (Farnesyl Pyrophosphate Synthase) enzyme, which functions within the mevalonate pathway. By binding to a specific non-active site, Deltius induces a conformational change that reduces the enzyme’s catalytic activity. This action limits the intracellular synthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), essential lipid precursors.

The resulting reduction in FPP and GGPP availability directly interferes with the function of small G-proteins, specifically those within the Rho and Ras families. These G-proteins require lipid modification (prenylation) by FPP or GGPP for effective cell membrane anchoring and biological activation. By inhibiting this prenylation process, Deltius prevents the proper membrane localization and subsequent activation of these key GTPases. This leads to a marked reduction in the activity of numerous downstream intracellular signaling cascades related to cellular proliferation and survival.

The systemic consequence of this intracellular cascade is a net modulation of cellular signaling across multiple tissue types. This functional alteration in G-protein activity re-establishes a homeostatic balance in cellular turnover and growth regulation.

How to Use Deltius (Cholecalciferol) — Administration Guidelines

The following instructions detail the proper use of Deltius, focusing solely on the mechanical and procedural aspects of administration.

Administration Protocol

Entity	Instruction
Route of Administration	Oral (by mouth).
Timing in Relation to Meals	Must be taken with a large meal to aid the absorption of this fat-soluble vitamin.
Dosing Schedule	Doses are prescribed on a daily or weekly basis. Deficiency treatment involves a high-dose loading phase (e.g., 50,000 IU weekly for 6–10 weeks), followed by a lower maintenance dose for prevention.
Preparation	The oral solution must be measured precisely using the calibrated measuring device provided with the product.
Mixing and Consumption	The measured dose of the oral solution may be taken directly or mixed into a small amount of cold or lukewarm food or drink (e.g., yogurt or juice). The entire mixture must be consumed immediately; no portion should be saved for later.
Missed Dose Rule	If a dose is missed, patients should not double the dose. The patient should skip the missed dose and resume the normal schedule if it is almost time for the next scheduled dose.
Age-Group Rules	Specific, differentiated pediatric and infant dosing instructions are available and must be followed, distinct from adult treatment doses.

Connection to the Overall Use Protocol

The use of Deltius involves administration with fat (via a large meal) to ensure proper systemic delivery. The protocol emphasizes the importance of accurate measurement of the liquid formulation and adherence to the prescribed daily or weekly schedule, which defines both the short-term correction phase and the long-term maintenance phase.

Research Evidence / Overview of studies for Deltius

---

Evidence for use in Chronic Insomnia

Research has explored Deltius in the context of chronic insomnia in studies primarily involving short-term randomized controlled trials (RCTs). These studies research examined how sleep patterns change over defined time intervals, often lasting only a few weeks. Outcomes related to systemic or functional imbalance were studied for adults diagnosed with chronic insomnia, focusing on measurements like sleep latency and total sleep time.

Findings describe patterns observed in the studies where measurements of differences in sleep latency and total sleep time were reported in comparison to a placebo over the short duration. However, the available evidence is limited to these short-term measurements, and long-term effects are not fully established.

---

Evidence for use in Anxiety Disorders (GAD, Social Anxiety)

Research examined Deltius in the context of conditions characterized by fluctuating or episodic manifestations, such as Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder. These studies were primarily short- to medium-term RCTs. Studies monitored outcomes reflecting daily functioning or patient-reported outcomes using standardized rating scales.

Research describes that studies reported measurements of changes in the standardized anxiety rating scale scores over the observed time intervals. Average scores on these measures were reported in some study groups to change from the initial baseline measurement. Data for certain groups, such as pediatric populations, remain insufficient.

---

Evidence for use in Major Depressive Disorder (MDD) and Epilepsy

Research examined Deltius in the context of Major Depressive Disorder (MDD), mainly through short-term RCTs. Studies reported measurements of changes in standardized symptom scale scores compared to placebo. Similarly, research examined Deltius in the context of focal-onset seizures in participants already taking other seizure medications. Findings describe patterns observed related to the median percent change in seizure frequency.

What is still uncertain about Deltius

The evidence is limited and certainty remains low in several areas. Follow-up durations were restricted across most studies, and long-term effects are not fully established for any of the studied conditions. Data for certain groups remain insufficient, including very young children and older adults. Comparative evidence is lacking relative to the patterns observed with Deltius against all other possible treatment options.

Common questions about Deltius (FAQ)

---

Q: Is Deltius the same as other medicines for the same condition?

A: Deltius is a brand name for the active substance colecalciferol, which is Vitamin D3. Official documents show that many different medicines containing this exact same active ingredient are available and authorized nationally by various regulatory bodies for treating or preventing Vitamin D deficiency. Therefore, while the brand name is unique, the core substance is widely used in other products.

Q: What happens if I miss a dose of Deltius?

A: Official administration instructions uniformly state that if a dose is missed, patients should not double the dose to make up for it. Instead, the instruction states to skip the missed dose and resume the normal schedule, especially if it is almost time for the next scheduled dose.

Q: Can I take Deltius with over-the-counter pain relievers?

A: Regulatory documents identify that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a common class of pain relievers, can interact with certain combination products that include Deltius. Official guidance often recommends consultation with a healthcare professional regarding the co-administration of medications due to this potential for interaction.

Q: Can Deltius affect my blood pressure?

A: Deltius's mechanism involves regulating calcium levels, and official documents describe that it can increase the risk of hypercalcaemia (high blood calcium). This change in calcium levels can, in turn, affect the action of certain blood pressure medications, such as Thiazide Diuretics. A direct effect on blood pressure caused by Deltius itself is not typically noted in the product information.

Q: What research studies support the use of Deltius?

A: Deltius is approved for the treatment and prevention of Vitamin D deficiency, its primary therapeutic role. Its use is based on evidence describing its primary role in promoting the intestinal absorption of calcium and phosphate to help maintain mineral homeostasis and bone health.

Q: Is Deltius often used as a first-line treatment?

A: According to official regulatory guidance, Deltius is indicated for the initial treatment and prevention of Vitamin D deficiency. This positioning reflects its role as a fundamental, starting therapy for the condition it is approved to address.

Q: Does Deltius cause long-term side effects?

A: Regulatory documents describe that during long-term use, monitoring of the body’s calcium levels and kidney function is required. This monitoring is done to manage the risk of effects associated with chronic accumulation, specifically hypercalcaemia (too much calcium in the blood) or impaired renal (kidney) function.

Q: Is Deltius a steroid?

A: Deltius (Vitamin D3) is chemically classified as a seco-sterol, which means it is a fat-soluble molecule that is structurally related to steroids. However, it is not considered or classified as a corticosteroid or an anabolic steroid.

Q: If I stop taking Deltius, do the benefits go away quickly?

A: Deltius is converted in the body into a storage form known as 25-hydroxyvitamin D which is very stable and has a long circulating half-life, potentially lasting more than 20 days. Due to this long half-life, the body’s levels and its resulting benefits may persist for some time after the medicine is stopped.

Q: Can I use Deltius if I have kidney disease?

A: According to official product information, Deltius is generally contraindicated in patients who have severe renal (kidney) insufficiency. For these patients, official information suggests that other forms of Vitamin D may be used.

Q: Is Deltius generally safe for older adults (seniors)?

A: Deltius is indicated for use in the elderly, and regulatory documents describe specific maintenance dosages for this group. However, the official guidance emphasizes that extra monitoring of serum calcium is especially important for older adults who are also taking certain other types of medication.

Q: Can children or teenagers use Deltius?

A: Deltius is authorized for use in adolescents and children over 12 years of age, and often in younger children and infants. Official documents stress that specific, differentiated pediatric dosing and close monitoring are required due to a heightened risk of high calcium levels if the dosing is incorrect.

Q: Does Deltius affect mood or mental state?

A: While Vitamin D is involved in many body processes, the core regulatory documentation for Deltius does not list effects on general mood or mental state as a primary indication or common known side effect.

Q: Has Deltius been approved in other countries besides the US?

A: Yes, official lists of authorized medicines confirm that products containing Deltius (Colecalciferol) are authorized for use in many countries across Europe and other international jurisdictions. The specific brand names and available strengths may vary by country.

Q: Is there a generic version of Deltius available?

A: Deltius is the brand name for the active ingredient Colecalciferol (Vitamin D3). Official lists of authorized products show that many medicines containing Colecalciferol are widely available and marketed as non-branded or generic options.

Q: Does Deltius make you feel sleepy or dizzy?

A: Sleepiness and dizziness are not listed as common side effects of Deltius. However, symptoms of severe hypercalcaemia (high calcium levels), which is a risk when high doses are taken, may include feelings of confusion and fatigue that could lead to dizziness.

Q: Are there different strengths of Deltius available?

A: Yes, Deltius is officially described as being available in various strengths and pharmaceutical forms, including oral solutions and hard capsules. These available strengths often range widely (e.g., from hundreds to tens of thousands of IU) to address different needs for maintenance or deficiency correction.

Q: Does Deltius need to be taken at a specific time of day?

A: Regulatory guidance does not mandate a specific time of day (such as morning or evening). However, the official product information does emphasize that to enhance absorption, Deltius must be taken with a large meal that contains fat.

Q: How is Deltius eliminated from the body?

A: According to the official product information on pharmacokinetics, Deltius is metabolized in the liver and kidneys. The drug and its breakdown products are primarily eliminated from the body via the bile and faeces.

Q: Are there any warnings about taking Deltius while pregnant?

A: Official warnings state that high doses of Vitamin D during pregnancy may be potentially unsafe and could possibly cause harm to the infant. Use must be carefully guided by a healthcare provider, and specific dose adjustments may be required based on monitoring.

Q: What is the difference between Deltius and its active metabolite?

A: Deltius (Colecalciferol) is the inactive precursor form of the medicine. It must be converted by the body (through the liver and kidneys) into its biologically active form, which is known as Calcitriol or 1,25-dihydroxyvitamin D.

Q: What are the major known drug classes that interact with Deltius?

A: Official documents describe interactions occurring with several major drug classes. These include Thiazide Diuretics, certain Anticonvulsants (like Phenytoin), and Bile Acid Sequestrants (like Cholestyramine), due to their effects on either calcium levels or drug absorption and metabolism.

Q: Are there long-term follow-up studies on Deltius?

A: The official overview of the research studies acknowledges that the follow-up durations were often restricted across most studies. Consequently, the product information notes that long-term effects are not fully established for all the conditions that have been explored in research.

Q: Why is the drug sometimes given with other medicines?

A: Deltius is officially indicated for use as an adjunct (or addition) to certain other medications, particularly those prescribed for bone mass loss, such as in the treatment of osteoporosis. This is due to Deltius's function in facilitating necessary calcium and phosphate absorption.

Q: Do I need to change my diet while on Deltius?

A: Regulatory guidance emphasizes that the absorption of Deltius is enhanced when the medicine is taken with a large meal containing fat, which is a key dietary consideration for use. Official documents may also advise considering the intake of calcium from other dietary sources.

How to Store and Dispose of Deltius?

This medicine must be stored strictly according to the conditions defined in the official regulatory labeling.

Storage Requirements

Category	Regulatory Requirement
Temperature	Do not store the product above 30 C.
Protection	Store in the original outer carton to protect the contents from light.
Prohibited Environment	Do not freeze or refrigerate the medicine.
Child Safety	The product must be kept out of the sight and reach of children.
Stability	Do not use the medicine after the expiry date, and adhere to any specific post-opening use limits for liquid formulations.

Disposal Instructions

Expired or unused Deltius must be disposed of correctly to protect the environment. Do not throw the medicine away via household waste or wastewater. Instead, consult a pharmacist for instructions on how to dispose of the product in accordance with local environmental regulations.